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Regarding “Right atrial bypass grafting for central
venous obstruction associated with dialysis access:
another treatment option”
To the Editors:
The paper by Dr El-Sabrout et al (J Vasc Surg
1999;29:472-8) addresses an important subject that has
plagued large referral centers and raises multiple questions.
First, central venous stenosis has been recognized as a
common problem associated with catheter hemodialysis 
as early as two decades ago.1 It has recently become more
prominent, with 38% of patients having temporary
catheters and 27% having permanent catheters, according
to the 1996 to 1998 Dialysis Outcomes Practice Patterns
Study, despite the lowest primary catheter patency rate of
9% at 1 year. Catheter access combined with other types of
vascular access has taken a toll of 6% of the estimated $14.6
billion spent on patients with end-stage renal disease in
1996 (1998 US Renal Data System report).2 Patients who
initiate urgent hemodialysis without a permanent access
have a 1-year mortality rate of 20% to 30% versus 15% to
20% in patients with stabilized conditions. This increase in
mortality rate relates to the risks inherent to the insertion
of a central venous catheter for hemodialysis. Furthermore,
subclavian vein placement of these catheters should be pro-
hibited because of the likelihood of subclavian vein steno-
sis, which will hamper future long-term access of the ipsi-
lateral arm. This has prompted the National Kidney
Foundation to recommend that: (1) hemodialysis access
should be created when the creatinine level is 4.0 mg/dL
(glomerular filtration rate, <20 mL/min);3,4 (2) catheter
use should be de-emphasized; and (3) native arteriovenous
fistulas should be the access of choice for patients who
require dialysis within 6 months, the typical access being
described three decades ago.5
Second, the therapy of central venous stenosis has
been more than deceiving, despite the most sophisticated
interventional radiology means, such as angioplasty intro-
duced in 19836 and the use of vascular stents.7 Hence, the
current article.
The authors’ claim that right atrial bypass grafting is a
therapeutic option is not born out by the presentation and
is highly controversial. First, only two patients had innom-
inate/superior vena cava obstruction and required a more
central bypass graft if repeated angioplasty failed constant-
ly. Incidently, these patients died at 2 and 39 months,
respectively, from the procedure. Second, the remaining
patients should have undergone axillary vein to jugular vein
bypass grafting instead, either directly or with a graft if the
opposite site was contemplated for outflow. Jugular vein
patency can be assessed easily with noninvasive Doppler
scan study or with direct contrast material injection.
Conventional upper extremity venogram is not appropriate
in delineating jugular vein anatomy. Third, the authors’
decision to avoid the internal jugular vein because “PTFE
[polytetrafluoroethylene] infection is common in these
patients” is contradictory by itself because infection of a
right atrial bypass graft would be catastrophic and more
difficult to handle than a bypass graft to the jugular vein.
Prior literature on the use of native veins, introduced as
early as 1976,8,9 jugular veins,10,11 or grafts have reported
high success rates. Finally, it is hoped that patient 8 did not
undergo a left brachial artery to right atrium bypass graft-
ing as printed. This would be difficult to justify, and no one
would use the left atrium as the next objective to bypass.
The authors were right to characterize the technique
as a procedure of magnitude.
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